In the biotech industry, we definately measure the age of the CA and PA, since this is something that the FDA would also look at. If aging isn't watched closely, it can be shocking the amount of time that a CA or PA will linger, making it very difficult to defend to the FDA.
Sandra
I would think that regardless of industry a large amount of time for a lingering CA or PA is also reflective of a failure to comply to ISO section 6.1 Provision of Resources.
If a CA or PA remains unaddressed for a long enough period of time that would be reflective of the companies inability to provide the appropriate resources to effectively deal with these issues. Whether it be financially or man-power, a lack of resources is generally at the root cause, unless the rare occasion where NO CORRECTIVE ACTION is even conceivable, and this could reflect a potentially larger problem.
In my company we are very small, 6 people, so if there is an issue that requires corrective action we attempt to rectify the situation as fast as possible. Sometimes this is dependent upon our suppliers (sending incorrect part, inappropriate packing slips, no mfg certs, etc) and cannot be done as fast as we would like, but even in these instances the corrective actions dependence upon our supplier is documented and someone is assigned to follow up on it until it is rectified.
As for a specific time frame of a CA lingering to long, I am not experienced enough to say. But if a CA remained open in our company for more than 2 weeks for non-product issues and a month for product related issues, I would be very distraught with my co-workers!